Amarex Taiwan is an affiliate of Amarex Clinical Research,

a full-service, international CRO with extensive experience successfully performing clinical studies across all phases of research and

discovery, development, validation and approval.

COVID-19

ACTIVITIES

IMAG1099.jpg
  • LinkedIn Social Icon
  • Facebook
  • Twitter
  • YouTube
22 October 2020

U.S. FDA Grants Fast Track Designation to Amarex Client PRG S&T Inc.

Amarex Taiwan, LLC, an NSF International company announced that the U.S. FDA granted Fast Track designation to Amarex’s client PRG S&T Inc. for PRG’s drug Progerinin, being tested as a treatment for Hutchinson-Gilford Progeria Syndrome (HGPS) and Werner Syndrome (WS). The Phase I study will be conducted in healthy subjects.

13 October 2020

Free webinar : Oncology Clinical Trials: An Emerging Paradigm Shift in Trial Design| October 27, 2020 11:00 AM EDT

Amarex Taiwan, LLC, an NSF International company’s Senior Vice President of Clinical Operations, Dr. Kush Dhody, will conduct a free webinar on Tuesday, October 27, 2020 at 11:00 a.m. EDT entitled Oncology Clinical Trials: An Emerging Paradigm Shift in Trial Design.

Register for this free webinar.

08 October 2020

Amytrx Enrolling Clinical Trial of AMTX-100 in Patients with Atopic Dermatitis

Amarex client, Amytrx Therapeutics (“Amytrx”), recently initiated clinical testing of their anti-inflammatory therapeutic product AMTX-100 for dermatological diseases and conditions with the enrollment of patients in a first-in-man Phase 1/2b study for treatment of mild to moderate atopic dermatitis.

22 September 2020

Amarex to Support AIM ImmunoTech in Regulatory Filings for Exciting Pancreatic Cancer Treatment under Development

Amarex Taiwan, LLC (Amarex) client AIM ImmunoTech Inc. (NYSE American: AIM) today announced receipt of statistically significant positive pancreatic cancer survival results from a multi-year Early Access Program (EAP) conducted at Erasmus Medical Center in the Netherlands.

Recommended by the people who matter most: our clients.

Chief Medical Officer

A Maryland Biotech Company

We have worked with Amarex on numerous projects and they consistently deliver high quality reliable service by leveraging a broad array of clinical and regulatory expertise. What sets them apart from other CROs is a creative entrepreneurial approach to drug development. They go beyond the technical aspects of clinical trial development and work with the sponsor to drive value and increase chances for success.

 5/5

★★★★★

Chief Technical Officer

A Canadian-based Infectious Diseases Organization

[Thank you to the team at Amarex] for the statistical support which proved to be invaluable and completely accurate in the final review by FDA. The cornerstone of this milestone achievement was the data from the clinical study, including the limit of detection study, and we came through [all FDA reviews with solid outcomes throughout]. From all of us here, a sincere thank you and well done to all at Amarex who worked on this project. We look forward to working with you again as we apply the successful platform to other diagnostic device developments in the future.

 5/5

★★★★★

2F., No.19-10, Sanchong Rd., Nangang District, Taipei 115, TAIWAN |  +886-2-26553391

20.jpg